The company reported positive results from a trial of the heart drug that the company is counting on for much of its growth.

Merck (MRK) stock in focus as the company urges shareholders to reject a mini-tender offer which stands at a 25% discount to ...

Merck has bullish valuation metrics and is trading above its 30-week EMA with bullish long-term momentum. Learn why MRK stock ...

Over the past two years, Merck ( MRK 0.19%) has faced several challenges, resulting in a decline in the company's share price ...

Are you wondering if Merck KGaA is undervalued, overvalued, or finally priced just right? Let's demystify the numbers together and see if there's opportunity hiding beneath the surface. Despite its ...

One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed ...

Merck’s MRK shares have risen 9.6% in a month. The company’s stock declined after it announced third-quarter results. Though ...

Merck has announced plans to acquire Cidara Therapeutics for $9.2 billion, or $221.50 per share. Representing a heavy premium ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company's common stock ...

ORLANDO, FL / ACCESS Newswire / November 14, 2025 / RedChip Companies, an industry leader in investor relations, media, and ...

On Friday alone, Cidara Therapeutics Inc. (NASDAQ:CDTX) climbed to as high as $218.85 before trimming gains to end the day ...